Vérez described the result as “very comforting,” because it has been obtained in a scenario of circulation “of the most worrying variants due to their transmissibility.”
Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.
Brukinsa® (zanubrutinib) is under regulatory review for relapsed, refractory MCL in the Russian Federation with potential approval at the end of the 2021.